- Home
- GLMD vs ALLR Comparison
GLMD vs ALLR Comparison
Compare GLMD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- ALLR
- Stock Information
- Founded
- GLMD 2000
- ALLR 2004
- Country
- GLMD Israel
- ALLR United States
- Employees
- GLMD N/A
- ALLR N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- ALLR Health Care
- Exchange
- GLMD Nasdaq
- ALLR Nasdaq
- Market Cap
- GLMD 4.6M
- ALLR 4.7M
- IPO Year
- GLMD 2014
- ALLR N/A
- Fundamental
- Price
- GLMD $2.94
- ALLR $1.32
- Analyst Decision
- GLMD
- ALLR
- Analyst Count
- GLMD 0
- ALLR 0
- Target Price
- GLMD N/A
- ALLR N/A
- AVG Volume (30 Days)
- GLMD 31.0K
- ALLR 2.4M
- Earning Date
- GLMD 11-14-2024
- ALLR 03-07-2025
- Dividend Yield
- GLMD N/A
- ALLR N/A
- EPS Growth
- GLMD N/A
- ALLR N/A
- EPS
- GLMD N/A
- ALLR N/A
- Revenue
- GLMD N/A
- ALLR N/A
- Revenue This Year
- GLMD N/A
- ALLR N/A
- Revenue Next Year
- GLMD N/A
- ALLR N/A
- P/E Ratio
- GLMD N/A
- ALLR N/A
- Revenue Growth
- GLMD N/A
- ALLR N/A
- 52 Week Low
- GLMD $2.56
- ALLR $0.90
- 52 Week High
- GLMD $23.80
- ALLR $288.00
- Technical
- Relative Strength Index (RSI)
- GLMD 47.92
- ALLR 64.99
- Support Level
- GLMD $2.84
- ALLR $0.96
- Resistance Level
- GLMD $3.02
- ALLR $1.07
- Average True Range (ATR)
- GLMD 0.23
- ALLR 0.17
- MACD
- GLMD -0.01
- ALLR 0.03
- Stochastic Oscillator
- GLMD 18.29
- ALLR 48.65
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.